Notice of posting of prospectus

RNS Number : 1236H
Oxford Biomedica PLC
06 July 2012
 



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

 

THE CONTENTS OF THIS ANNOUNCEMENT DO NOT CONSTITUTE OR FORM PART OF AN OFFER OF OR INVITATION TO SELL OR ISSUE OR ANY SOLICITATION OF ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SECURITIES FOR SALE IN ANY JURISDICTION NOR SHALL THEY (OR ANY PART OF THEM) OR THE FACT OF THEIR DISTRIBUTION FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, OR ACT AS AN INDUCEMENT TO ENTER INTO, ANY CONTRACT OR COMMITMENT TO DO SO.  THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND NOT A PROSPECTUS FOR THE PURPOSES OF EU DIRECTIVE 2003/71/EC (THE "DIRECTIVE") AND PART VI OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 AS AMENDED.  A PROSPECTUS WILL BE PREPARED AND MADE AVAILABLE TO THE PUBLIC IN ACCORDANCE WITH THE DIRECTIVE.  RECIPIENTS OF THIS ANNOUNCEMENT WHO INTEND TO PURCHASE SUCH SECURITIES ARE REMINDED THAT ANY SUCH PURCHASE OR SUBSCRIPTION MUST BE MADE SOLELY ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS IN ITS FINAL FORM.

 

THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION.  NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES AND THE COMPANY DOES NOT CURRENTLY INTEND TO REGISTER ANY SECURITIES UNDER THE SECURITIES ACT. THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES.

 

06 July 2012

 

Oxford BioMedica plc ("Oxford BioMedica" or the "Company")

 

Notice of posting of prospectus

 

Further to the announcement of 29 June 2012 of the Company's proposed Firm Placing and Open Offer of up to £16 million, Oxford BioMedica announces that a Prospectus in connection with the Firm Placing and Open Offer was approved by the UK Listing Authority (the "UKLA") earlier today.

 

The Prospectus is expected to be posted to shareholders today and copies of the Prospectus will shortly be available for inspection at www.hemscott.com/nsm.com.

 

The Prospectus contains a notice of general meeting to, inter alia, approve the Firm Placing and Open Offer which will be held at the offices of Covington & Burling LLP at 265 Strand, London, WC2R 1BH.

 

The Prospectus will shortly be available to view on the Company's website at www.oxfordbiomedica.co.uk in the "Investors" section.  Copies of the Prospectus will also be available for inspection at the Company's offices at Oxford BioMedica plc, Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA during usual business hours on any weekday (Saturday, Sunday and public holidays excepted).

 

Expected Timetable of Principal Events

 

Record Date for entitlements under the Open Offer

Close of business on 28 June 2012

Announcement of Firm Placing and Placing and Open Offer

29 June 2012

Ex-entitlement date

8.00 a.m. on 29 June 2012

Despatch of Prospectus, Application Forms and Forms of Proxy

6 July 2012

Open Offer Entitlements credited to stock accounts in CREST of Qualifying CREST Shareholders

as soon as possible after

8.00 a.m. on 7 July 2012

Latest recommended date for requested withdrawal of Open Offer Entitlements from CREST

4.30 p.m. on 17 July 2012

Latest recommended date for depositing Open Offer Entitlements into CREST

3.00 p.m. on 18 July 2012

Latest time and date for splitting Application Forms (to satisfy bona fide market claims)

3.00 p.m. on 19 July 2012

Latest time and date for receipt of Forms of Proxy

9.30 a.m. on 23 July 2012

Latest time and date for receipt of completed Application Forms and payment in full under the Open Offer or settlement of relevant CREST instructions (as appropriate)

11.00 a.m. on 23 July 2012

Results of the Firm Placing and Placing and Open Offer announced through an RIS

25 July 2012

General Meeting

9.30 a.m. on 25 July 2012

Admission and commencement of dealings in the New Ordinary Shares expected to commence


8.00 a.m. on 26 July 2012

CREST stock accounts expected to be credited for the New Ordinary Shares

as soon as possible after

8.00 a.m. on 26 July 2012

Share certificates for New Ordinary Shares expected to be despatched

within 7 days of admission

 

 

For further information please contact:

 

Oxford BioMedica plc

Tel: +44 (0)1865 783 000

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

Lara Mott, Head of Corporate Communications




Singer Capital Markets Limited

Tel: +44 (0)20 3205 7500

(Financial Adviser, Sponsor, Broker and Underwriter)

Shaun Dobson


Claes Spång

Jenny Wyllie




WG Partners

(Adviser and Placing Agent)

David Wilson


Jonathan Gosling          

Tel: +44 (0)20 7149 6000

 

Media Enquiries:

Mary Clark

Sarah Macleod

Claire Dickinson

M:Communications       

  

Tel: +44 (0)20 7920 2360

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

MSCUNVARUWABRAR